T Cell Lymphoma clinical trials at UC Davis

• Study of Experimental medicine, Anti-ICOS Monoclonal Antibody MEDI-570, in the treatment of Non-Hodgkin's Lymphoma

  “Immunotherapy (Anti-ICOS Monoclonal Antibody MEDI-570) study of side effects, best dose, and helpfulness in treatment of Lymphoma”

  open to eligible people ages 18 years and up

  This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

  Sacramento, California and other locations

Last updated: September 15, 2020